Boston Trust Walden Corp Trims Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Boston Trust Walden Corp trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 40.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 899,061 shares of the biotechnology company’s stock after selling 614,914 shares during the period. Boston Trust Walden Corp’s holdings in Corcept Therapeutics were worth $45,304,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in CORT. Hancock Whitney Corp boosted its holdings in shares of Corcept Therapeutics by 1.2% in the third quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock valued at $1,062,000 after purchasing an additional 270 shares during the period. KBC Group NV raised its position in Corcept Therapeutics by 21.3% during the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 496 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Corcept Therapeutics by 20.3% in the 4th quarter. GAMMA Investing LLC now owns 2,996 shares of the biotechnology company’s stock worth $151,000 after buying an additional 506 shares during the period. Capital Performance Advisors LLP bought a new position in shares of Corcept Therapeutics during the 3rd quarter worth $25,000. Finally, Bank of Montreal Can increased its stake in shares of Corcept Therapeutics by 5.0% during the second quarter. Bank of Montreal Can now owns 12,156 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 580 shares during the period. 93.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CORT. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Trading Down 0.6 %

NASDAQ CORT opened at $66.55 on Tuesday. Corcept Therapeutics Incorporated has a 52 week low of $20.84 and a 52 week high of $71.29. The company has a 50 day moving average price of $56.17 and a 200 day moving average price of $47.33. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm has a market cap of $6.97 billion, a PE ratio of 52.82 and a beta of 0.58.

Insiders Place Their Bets

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $50.54, for a total transaction of $111,188.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the transaction, the insider now directly owns 8,494 shares of the company’s stock, valued at $481,779.68. The trade was a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,011 shares of company stock valued at $1,461,568. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.